Oxaliplatin Market 2019: Association between Major Key Vendors Like ABB Inc to Produce Promising Growth Opportunities in Upcoming Years, says Straits Research

The global oxaliplatin market is expected to reach USD 548.6 million in 2028 from USD 981.99 million in 2018 at a negative CAGR of 5.7% during the forecast period 2019–2026. Oxaliplatin, an antineoplastic chemotherapy drug, is used to treat metastatic colorectal cancer. The drugs is administered in combination with fluorouracil and leucovorin.

Chemotherapy is preferred at the stage III and stage IV, owing to which, the scope of the treatment therapy is limited. Declining market can also be attributed to the growing preference for other therapies and rising number of new molecules under clinical studies. The effectiveness of the molecules currently under development, are found to exhibit potent results, compared to oxaliplatin. The side effects of the alternative therapies are also comparatively less. However, ongoing scenario might change in future, if oxaliplatin gets approval for other indications.

Get a Sample Copy of this report with the latest Industry trends and COVID-19 Impact: 
https://straitsresearch.com/report/oxaliplatin-market/request-sample

The Major Players Covered in this Report: Sanofi, Pfizer, Yakult Honsha, and Dr. Reddy’s laboratory., & More...

By Type, Lyophilized Powder, Aqueous Solutions
By Application, Adjuvant Treatment of Stage III Colon Cancer, Treatment of Stage IV Colorectal Cancer, Other Applications
By End Users, Hospitals and Clinics, Research Institutes, Other End Users

Buy Full Report with Detail Analysis with COVID-19 Impact – 
https://straitsresearch.com/buy-now/oxaliplatin-market/global/

Growing Domestic Demand and Expanding Pharmaceutical Sector to Drive the Demand for Oxaliplatin in the APAC Region:
Asia-Pacific region is anticipated to hold the largest market share in the global Oxaliplatin market during the forecast period 2019-2026. The growth in this region can be attributed to the presence of emerging economies like India, China, Japan, Vietnam, and Indonesia, which account for the largest share in this region. India is one of the largest producers of Oxaliplatin and a major exporter of the product to various countries across the globe. India accounts for around 80% of the world’s exports of Oxaliplatin. The favorable climatic conditions and growth of agricultural inputs and allied services like cold storage and warehousing in India are prompting higher production.

View Full Report @ https://straitsresearch.com/report/oxaliplatin-market/global/

Our Report Covers
Historical inferences, findings & analysis of the market from 2013 to 2018
Projections and performance forecast analysis for the future from 2019 to 2028
Production and consumption point of view (POV) analysis
Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects

Key Findings:
The introduction of generics and emergence of alternative therapies, has resulted in the decline of the market size
The preference for alternative therapies is increasing at a rapid rate owing to the better efficiency and less side effects as compared to oxaliplatin
Rising screening programs for colorectal cancer has improved the diagnosis at earlier stages, wherein, the tumor is removed surgically, which reduces the chances of chemotherapy to treat the colorectal cancer
The market dynamics might change in the future, if the approvals for other disease indications rises significantly
In terms of the product type, lyophilized powder segment accounted for 53.9% in 2018 and it was valued at USD 529.62 million
In the current scenario, the adoption of oxaliplatin to treat metastatic cancer is the highest in North America, owing to which it holds the largest share with 43.7%. The North America oxaliplatin market was valued at USD 428.9 million in 2018 and expected to reach 223.8 million by 2028, at a negative CAGR of -6.3%
The rate of market decline will be lowest in the developing economies as the adoption of substitute therapies is the lowest in these regions. Moreover, the awareness of colorectal cancer screening programs is also less. At stage III or stage IV, the preferred treatment to treat colorectal cancer is chemotherapy. Thus, the market is declining at comparatively slow rates in the developing economies
Asia Pacific was valued at 192.9 million in 2018 and expected to reach USD 126.7, at a negative CAGR of -4.2%

View this report with a detailed description and TOC @ 
https://straitsresearch.com/report/oxaliplatin-market/toc

For more details, please contact us -
Straits Research
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY 10022
Tel: +1 646 480 7505, +44 208 068 9665
Website: https://straitsresearch.com/

About Us:
Regardless of whether you're looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with what customers purchase. We overcome the issues of our customers by recognizing and deciphering just the target group, while simultaneously generating leads with the highest precision. We seek to collaborate with our customers to deliver a broad spectrum of results through a blend of market and business research approaches.

This release was published on openPR.